279 results on '"Fürst, Sabine"'
Search Results
2. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome
Catalog
Books, media, physical & digital resources
3. Cord blood transplantation for adult mature lymphoid neoplasms in Europe and Japan
4. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies
5. Post-CAR-T Cell Therapy (Consolidation and Relapse): Lymphoma
6. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
7. Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome
8. Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients
9. Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry
10. A Single Center Real World Experience of Allogeneic HSCT of Patients with MDS/CMML in Aged Population
11. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison
12. Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation
13. Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients
14. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
15. Killer Cell Immunoglobulin-Like Receptor–Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell–Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide
16. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD
17. Oxidation is an underappreciated post-translational modification in the regulation of immune responses associated with changes in phosphorylation
18. Haploidentical T Cell–Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen–Matched Related or Unrelated Donor
19. Oxidation is an underappreciated post-translational modification in the regulation of immune responses associated with changes in phosphorylation
20. Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: Outcomes of patients admitted to intensive care unit
21. Decreased Nonrelapse Mortality after Unrelated Cord Blood Transplantation for Acute Myeloid Leukemia Using Reduced-Intensity Conditioning: A Prospective Phase II Multicenter Trial
22. An Elite Sport-Inspired Coaching Strategy for Patients after Allogeneic Hematopoietic Stem Cell Transplantation: The Rebond Program
23. Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared with Matched Related or Unrelated Donor Transplantation
24. Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease
25. Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies
26. Double umbilical cord blood transplantation for hematological malignancies: A long-term analysis from the SFGM-TC registry
27. Response to Immunosuppressive Treatment Predicts Outcome in Patients with Chronic Graft-versus-Host Disease: A Single-Center Analysis of Longitudinal Data
28. Post-transplant cyclophosphamide versus antithymocyte globulin as GVHD prophylaxis for 10/10 HLA-matched unrelated allogeneic hematopoietic stem cell transplantation.
29. Low incidence of chronic GVHD after HLA‐haploidentical peripheral blood stem cell transplantation with post‐transplantation cyclophosphamide in older patients
30. Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies
31. Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor
32. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
33. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor
34. Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome
35. Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases
36. Randomized Study of 2 Reduced-Intensity Conditioning Strategies for Human Leukocyte Antigen-Matched, Related Allogeneic Peripheral Blood Stem Cell Transplantation: Prospective Clinical And Socioeconomic Evaluation
37. Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome
38. Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma
39. Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD
40. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma
41. Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens
42. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study
43. Identification and characterisation of Escherichia coli strains of O157 and non-O157 serogroups containing three distinct Shiga toxin genes
44. Haplo Allogeneic Hematopoietic Stem Cell Transplantation in Patients of 65 Years or Older: A Monocenter Analysis
45. Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation
46. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
47. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 + cells
48. Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
49. Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Patients > 60 Years with Acute Myeloid Leukemia in First Complete Remission: A 10-Year Single Center Transplantation Program Analysis
50. Allogeneic Hematopoietic Stem Cell Transplantation for Patients Over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.